Real-world data: towards achieving the achievable in cancer care
CM Booth, S Karim, WJ Mackillop - Nature reviews Clinical oncology, 2019 - nature.com
The use of data from the real world to address clinical and policy-relevant questions that
cannot be answered using data from clinical trials is garnering increased interest. Indeed …
cannot be answered using data from clinical trials is garnering increased interest. Indeed …
Examining the use of real‐world evidence in the regulatory process
The 21st Century Cures Act passed by the United States Congress mandates the US Food
and Drug Administration to develop guidance to evaluate the use of real‐world evidence …
and Drug Administration to develop guidance to evaluate the use of real‐world evidence …
[HTML][HTML] Digital transformation in healthcare–architectures of present and future information technologies
G Gopal, C Suter-Crazzolara, L Toldo… - Clinical Chemistry and …, 2019 - degruyter.com
Healthcare providers all over the world are faced with a single challenge: the need to
improve patient outcomes while containing costs. Drivers include an increasing demand for …
improve patient outcomes while containing costs. Drivers include an increasing demand for …
Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting
JC Simeone, BL Nordstrom, K Patel, AB Klein - Future Oncology, 2019 - Taylor & Francis
Aim: To conduct a retrospective analysis of electronic medical record data to understand real-
world treatment patterns and overall survival (OS) in patients with metastatic non-small-cell …
world treatment patterns and overall survival (OS) in patients with metastatic non-small-cell …
[HTML][HTML] Immunotherapy in non-small cell lung cancer: Update and new insights
X Mielgo-Rubio, EA Uribelarrea, LQ Cortés… - Journal of clinical and …, 2021 - ncbi.nlm.nih.gov
Background: The treatment of non-small-cell lung carcinoma (NSCLC) has changed
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …
markedly in recent years as a result of two major treatment milestones: Targeted therapy and …
[HTML][HTML] Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States
Background Clinical trials have demonstrated the efficacy of several life-prolonging
therapies for metastatic castration-resistant prostate cancer (mCRPC); however, real-world …
therapies for metastatic castration-resistant prostate cancer (mCRPC); however, real-world …
Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non–small …
PURPOSE Large, generalizable real-world data can enhance traditional clinical trial results.
The current study evaluates reliability, clinical relevance, and large-scale feasibility for a …
The current study evaluates reliability, clinical relevance, and large-scale feasibility for a …
Roles of the RANKL–RANK axis in antitumour immunity—implications for therapy
Recognizing that the transformative effects of immunotherapy are currently limited to a
minority of patients with cancer, research efforts are increasingly focused on expanding and …
minority of patients with cancer, research efforts are increasingly focused on expanding and …
Immune checkpoint inhibitors in real‐world treatment of older adults with non–small cell lung cancer
E Muchnik, KP Loh, M Strawderman… - Journal of the …, 2019 - Wiley Online Library
OBJECTIVE To evaluate the efficacy and toxicity of immune checkpoint inhibitors (ICIs) in
older patients with advanced non–small cell lung cancer (NSCLC) seen in routine clinical …
older patients with advanced non–small cell lung cancer (NSCLC) seen in routine clinical …
FDA analyses of survival in older adults with metastatic non–small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies
S Marur, H Singh, P Mishra-Kalyani, E Larkins… - Seminars in …, 2018 - Elsevier
Background Among patients with newly diagnosed non–small cell lung cancer (NSCLC),
approximately 70% occur in those above 65 years of age and more than half are metastatic …
approximately 70% occur in those above 65 years of age and more than half are metastatic …